How COVID-19 Is Bending the Curve on Vaccine Development and Manufacturing Norms
Summary: The COVID-19 pandemic is requiring a significant reduction in vaccine development and clinical trial timelines. The stakes are high and it’s all-hands-on-deck for sponsor companies, contract providers, and suppliers who are collaborating to overcome these obstacles. Hear Mike Riley, Catalent Biologics Region President, North America, address challenges in manufacturing scale-up and discuss how partnerships are enabling pharma companies of all sizes to meet unprecedented timelines as they race toward delivering vaccines to patients worldwide.